NO2385374T3 - - Google Patents

Info

Publication number
NO2385374T3
NO2385374T3 NO10162066A NO10162066A NO2385374T3 NO 2385374 T3 NO2385374 T3 NO 2385374T3 NO 10162066 A NO10162066 A NO 10162066A NO 10162066 A NO10162066 A NO 10162066A NO 2385374 T3 NO2385374 T3 NO 2385374T3
Authority
NO
Norway
Application number
NO10162066A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42315849&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO2385374(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of NO2385374T3 publication Critical patent/NO2385374T3/no

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2405/00—Assays, e.g. immunoassays or enzyme assays, involving lipids
    • G01N2405/04—Phospholipids, i.e. phosphoglycerides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2570/00—Omics, e.g. proteomics, glycomics or lipidomics; Methods of analysis focusing on the entire complement of classes of biological molecules or subsets thereof, i.e. focusing on proteomes, glycomes or lipidomes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/323—Arteriosclerosis, Stenosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicinal Preparation (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO10162066A 2010-05-05 2010-05-05 NO2385374T3 (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10162066.4A EP2385374B2 (en) 2010-05-05 2010-05-05 Lipidomic biomarkers for atherosclerosis and cardiovascular disease

Publications (1)

Publication Number Publication Date
NO2385374T3 true NO2385374T3 (zh) 2014-06-07

Family

ID=42315849

Family Applications (2)

Application Number Title Priority Date Filing Date
NO10162066A NO2385374T3 (zh) 2010-05-05 2010-05-05
NO11719802A NO2567240T3 (zh) 2010-05-05 2011-05-05

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO11719802A NO2567240T3 (zh) 2010-05-05 2011-05-05

Country Status (9)

Country Link
US (5) US9046538B2 (zh)
EP (3) EP2385374B2 (zh)
JP (1) JP5871244B2 (zh)
CN (1) CN102971633B (zh)
CA (1) CA2798238C (zh)
DK (2) DK2385374T4 (zh)
ES (2) ES2455124T5 (zh)
NO (2) NO2385374T3 (zh)
WO (1) WO2011138419A1 (zh)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9046540B2 (en) * 2008-09-29 2015-06-02 Plaxgen Inc. Assay, composition and non-enzymatic mechanism of statin in modulating lipid metabolism
CN102884435A (zh) 2009-11-27 2013-01-16 贝克Idi心脏和糖尿病研究院控股有限公司 用于稳定和不稳定心脏病的脂质生物标记物
BR112012018771A2 (pt) 2010-01-29 2017-06-20 Metanomics Gmbh ''método para dianosticar insuficência cardíaca em um sujeito''
EP2385374B2 (en) 2010-05-05 2018-02-28 Zora Biosciences OY Lipidomic biomarkers for atherosclerosis and cardiovascular disease
CA2801459C (en) * 2010-06-20 2018-04-24 Zora Biosciences Oy Lipidomic biomarkers for identification of high-risk coronary artery disease patients
US8765479B1 (en) * 2011-03-13 2014-07-01 Atherotech, Inc. Methods for determining the risk of coronary heart disease and clinical manifestations of coronary heart disease
US9541565B2 (en) 2011-04-08 2017-01-10 Zora Biosciences Oy Biomarkers for sensitive detection of statin-induced muscle toxicity
EP2592423A1 (en) 2011-11-08 2013-05-15 Zora Biosciences OY Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients not undergoing statin treatment
EP2592422A1 (en) * 2011-11-08 2013-05-15 Zora Biosciences OY Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients undergoing statin treatment
EP2642293A1 (en) 2012-03-22 2013-09-25 Nestec S.A. 9-oxo-octadecadienoic acid (9-oxo-HODE)as as biomarker for healthy ageing
EP2642295A1 (en) * 2012-03-22 2013-09-25 Nestec S.A. 1-O-alkyl-2-acylglycerophosphocholine (PC-O) 40:1 as biomarker for healthy ageing
ES2552371T3 (es) * 2012-05-25 2015-11-27 Zora Biosciences Oy Biomarcadores sensibles, eficaces e inocuos, para la inhibición de la Proproteína Convertasa Subtilisina/Kexina de tipo 9 (PCSK9)
CN103149312B (zh) * 2013-02-05 2015-02-04 东北农业大学 一种利用超高效液相色谱串联四级杆质谱分析婴儿乳粉中唾液酸的方法
EP2778686B1 (en) * 2013-03-13 2016-07-27 Academisch Ziekenhuis Leiden h.o.d.n. LUMC Lipidomics of familial longevity
CN105723223B (zh) * 2013-11-14 2019-04-09 雀巢产品技术援助有限公司 预测健康衰老的脂质生物标志物
KR101660328B1 (ko) 2014-01-14 2016-09-27 한국과학기술연구원 심혈관 질환 진단용 바이오 마커
NZ759799A (en) 2014-04-10 2022-12-23 MEP Equine Solutions LLC Method for the quantification of parasite eggs in feces
US9347960B2 (en) 2014-06-16 2016-05-24 Zora Biosciences, Oy Ceramides and their use in diagnosing CVD
EP3177939A1 (en) 2014-09-11 2017-06-14 Liposcience, Inc. Cardiovascular risk evaluations using a risk parameter that includes an hdl and inflammatory biomarker interaction parameter
US10996231B2 (en) 2014-12-16 2021-05-04 Washington University Ceramides for evaluating risk of cardiovascular disease
CA2973116C (en) * 2015-01-09 2023-08-15 Global Genomics Group, LLC Blood based biomarkers for diagnosing atherosclerotic coronary artery disease
EP3121599A1 (en) * 2015-07-23 2017-01-25 Medizinische Hochschule Hannover Analysis for atherosclerosis
WO2017029401A1 (en) * 2015-08-19 2017-02-23 Metanomics Gmbh Means and methods for diagnosing cardiac disease in a subject
WO2017028308A1 (en) * 2015-08-20 2017-02-23 Bgi Shenzhen Biomarkers for coronary heart disease
WO2017097852A2 (en) * 2015-12-07 2017-06-15 Zora Biosciences Oy Use of ceramides and lpls in diagnosing cvd
CN105445408B (zh) * 2016-01-25 2018-06-12 齐炼文 诊断区分冠状动脉粥样硬化和稳定型心绞痛的代谢标志物
CN105486778B (zh) * 2016-01-25 2017-11-03 齐炼文 诊断区分稳定型心绞痛和急性冠脉综合征的代谢标志物
CN108872404A (zh) * 2017-05-09 2018-11-23 中国科学院上海生命科学研究院 超长链饱和脂肪酸或其检测试剂在代谢综合征患病风险预测中的应用
CN107144624B (zh) * 2017-05-15 2021-01-05 中国科学院生态环境研究中心 甄别二氧化硅颗粒来源的方法
TWI835735B (zh) * 2017-06-12 2024-03-21 比利時商健生藥品公司 減少或預防第ii型糖尿病患者中心血管事件之方法
CN109870536B (zh) * 2017-12-05 2021-08-10 中国科学院大连化学物理研究所 一种基于液相色谱-质谱联用的高覆盖脂质组学分析方法
CN114062581A (zh) * 2017-12-14 2022-02-18 江苏豪思生物科技有限公司 一种用于评估冠状动脉疾病的试剂盒
WO2019119049A1 (en) * 2017-12-20 2019-06-27 Baker Heart and Diabetes Institute Method of predicting drug therapeutic responder status and methods of treatment
CN110433282B (zh) * 2018-05-04 2023-03-14 上海交通大学医学院附属瑞金医院 胰高血糖素样肽-1在制备治疗钙化性主动脉瓣疾病药物方面的应用
US20220003791A1 (en) * 2018-12-06 2022-01-06 Zora Biosciences Oy Biomarkers for cardiovascular events
US20220214367A1 (en) * 2019-04-15 2022-07-07 Board Of Regents, The University Of Texas System Calibration methods and compositions for biomolecule analysis
WO2020242796A1 (en) * 2019-05-28 2020-12-03 Ohio University Assays and methods for screening for cardiovascular disease using ldl subclasses and endothelial nitric oxide/peroxynitrite balance
CN112305122B (zh) * 2020-10-30 2021-07-13 河北医科大学第二医院 代谢物标志物及其在疾病中的应用
CN112305124B (zh) * 2020-10-30 2022-03-04 河北医科大学第二医院 一种生物标志物及其在疾病诊断中的应用
CN112147344B (zh) * 2020-10-30 2021-07-13 河北医科大学第二医院 动脉粥样硬化性脑梗死的代谢标志物及其在诊疗中的应用
CN112305119B (zh) * 2020-10-30 2021-08-17 河北医科大学第二医院 动脉粥样硬化性脑梗死的生物标志物及其应用
CN113782177A (zh) * 2020-12-02 2021-12-10 北京市心肺血管疾病研究所 一种用于鉴别诊断冠心病患者斑块稳定性的数据处理装置、系统
CN112630330B (zh) * 2020-12-08 2021-12-21 河北医科大学第二医院 小分子物质在脑梗死诊断中的应用
CA3217229A1 (en) * 2021-04-21 2022-10-27 Albert Einstein College Of Medicine Methods of stabilizing the neuronal proteome against collapse and protecting vascular cells
CN113295793B (zh) * 2021-05-20 2022-11-04 复旦大学附属中山医院 预测早期糖尿病以及糖尿病发生的生物标志物、其检测方法与应用
CN116087487A (zh) * 2021-11-08 2023-05-09 中国医学科学院阜外医院 糖尿病患者早期预测心血管疾病（cvd）的生物标志物及其用途
CN113960222B (zh) * 2021-12-23 2022-02-25 中国中医科学院医学实验中心 基于血清样本的胆汁酸全通路代谢轮廓的检测方法及其应用
CN113960221B (zh) * 2021-12-23 2022-02-25 中国中医科学院医学实验中心 基于粪便样本的胆汁酸全通路代谢轮廓的检测方法及其应用
CN114705873B (zh) * 2022-06-06 2022-08-26 首都医科大学宣武医院 脂质作为颈动脉粥样硬化斑块诊断标志物的用途
CN115267214A (zh) * 2022-08-10 2022-11-01 南方医科大学珠江医院 一种脂质代谢标志物、其筛选方法及其在颅内动脉瘤中的应用
WO2024192471A1 (en) * 2023-03-20 2024-09-26 Baker Heart and Diabetes Institute Methods of assessing metabolic health
CN118258931B (zh) * 2024-05-29 2024-08-16 山东第一医科大学附属省立医院(山东省立医院) 用于预警女性动脉粥样硬化的代谢标志物组合及检测试剂盒

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2293718A1 (en) * 1997-06-10 1998-12-17 Medlyte Diagnostics, Inc. Methods for early detection of heart disease
EP1264182B1 (de) 2000-03-03 2005-11-16 Schmitz, Gerd Verfahren zur analyse von exogener und endogener zell-aktivierung
US6664230B1 (en) 2000-08-24 2003-12-16 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
JP4062514B2 (ja) * 2001-01-02 2008-03-19 ザ・クリーブランド・クリニック・ファンデーション ミエロペルオキシダーゼ、心臓血管疾患についての危険性指示因子
ES2429528T3 (es) 2001-01-02 2013-11-15 The Cleveland Clinic Foundation Mieloperoxidasa, un indicador de riesgo para enfermedad cardiovascular
EP1417629B1 (en) * 2001-07-06 2008-02-20 Lipomics Technologies, Inc. Generating, viewing, interpreting, and utilizing a quantitative database of metabolites
CN100347727C (zh) 2002-06-28 2007-11-07 Nxp股份有限公司 具有用于检测存储装置所存储信息产生变化的检测装置的数据载体
AU2003286726A1 (en) 2002-10-25 2004-05-13 Metabolon, Inc. Methods for drug discovery, disease treatment, and diagnosis using metabolomics
WO2004085610A2 (en) * 2003-03-28 2004-10-07 Washington University In St. Louis Multidimensional mass spectrometry of serum and cellular lipids directly from biologic extracts
US20070244076A1 (en) * 2003-10-08 2007-10-18 Musc Foundation Research Development Site and Rate Selective Prodrug Formulations of D609 with Antioxidant and Anticancer Activity
CA2548313A1 (en) 2003-12-23 2005-07-14 Musc Foundation For Research Development Methods and compositions for the prevention and treatment of inflammatory diseases or conditions
EP1618876A1 (en) 2004-07-19 2006-01-25 Nederlandse Organisatie voor toegepast-natuurwetenschappelijk Onderzoek TNO Use of sphingolipids for prevention and treatment of atherosclerosis
FI20041340A0 (fi) 2004-10-15 2004-10-15 Jurilab Ltd Oy Menetelmä ja testipakkaus äkillisen sydäninfarktin riskin havaitsemiseksi
US20060135497A1 (en) * 2004-12-17 2006-06-22 Ajay Gupta Combination therapy for treating heart disease
EP1861091B1 (en) * 2005-03-03 2013-12-11 Vital Health Sciences Pty Ltd. Compounds having lipid lowering properties
EP1726962A1 (en) 2005-05-24 2006-11-29 Leiden University Medical Center Apolipoprotein E plasma levels for monitoring and reducing the risk of cardiovascular disease
US7972802B2 (en) 2005-10-31 2011-07-05 University Of Washington Lipoprotein-associated markers for cardiovascular disease
WO2007127192A2 (en) * 2006-04-24 2007-11-08 Duke University Lipidomic approaches to determining drug response phenotypes in cardiovascular disease
US8137977B2 (en) * 2006-04-24 2012-03-20 Children's Hospital & Research Center At Oakland Lipidomic approaches to determining drug response phenotypes in cardiovascular disease
CN101522910A (zh) * 2006-06-12 2009-09-02 佐拉生物科学有限公司 肌病的诊断方法
WO2007144467A1 (en) * 2006-06-12 2007-12-21 Zora Biosciences Oy Diagnostic method for myopathy
JP4611941B2 (ja) 2006-06-29 2011-01-12 トヨタ自動車株式会社 内燃機関の排気還流装置
DE102006034153B4 (de) 2006-07-24 2018-02-08 Magna powertrain gmbh & co kg Getriebe
ES2527438T3 (es) * 2006-08-08 2015-01-26 Metabolon, Inc. Marcadores de la hepatopatía grasa no alcohólica (NAFLD) y de la esteatohepatitis no alcohólica (NASH) y métodos de uso de los mismos
WO2008031917A1 (en) * 2006-09-14 2008-03-20 Zora Biosciences Oy Biofluid metabolite profiling as a tool for early prediction of autoimmunity and type 1 diabetes risk
EP2140271A2 (en) * 2007-03-26 2010-01-06 BG Medicine, Inc. Methods for detecting coronary artery disease
US20100179066A1 (en) 2007-06-07 2010-07-15 Inserm (Institut National De La Santé Et De La Rec Method for Assessing the Risk of a Cardiovascular Disease and for Diagnosing Dyslipidemia
US8026099B2 (en) * 2007-07-26 2011-09-27 Washington University Lipid profile as a biomarker for early detection of neurological disorders
WO2009132082A2 (en) * 2008-04-22 2009-10-29 Medical College Of Georgia Research Institute, Inc. Immunogenic compositions containing ceramide and methods of use thereof
US10241093B2 (en) * 2009-05-28 2019-03-26 The Cleveland Clinic Foundation Trimethylamine-containing compounds for diagnosis and prediction of disease
CN102884435A (zh) * 2009-11-27 2013-01-16 贝克Idi心脏和糖尿病研究院控股有限公司 用于稳定和不稳定心脏病的脂质生物标记物
BR112012018771A2 (pt) * 2010-01-29 2017-06-20 Metanomics Gmbh ''método para dianosticar insuficência cardíaca em um sujeito''
EP2385374B2 (en) 2010-05-05 2018-02-28 Zora Biosciences OY Lipidomic biomarkers for atherosclerosis and cardiovascular disease

Also Published As

Publication number Publication date
US20180321266A1 (en) 2018-11-08
CA2798238C (en) 2018-01-23
US9857386B2 (en) 2018-01-02
US20130045217A1 (en) 2013-02-21
DK2385374T4 (en) 2018-04-30
US10551394B2 (en) 2020-02-04
ES2672054T5 (es) 2021-11-22
JP5871244B2 (ja) 2016-03-01
EP2385374B1 (en) 2014-01-08
EP2567240B2 (en) 2021-03-03
JP2013527449A (ja) 2013-06-27
DK2385374T3 (en) 2014-03-17
ES2672054T3 (es) 2018-06-12
DK2567240T3 (en) 2018-06-14
ES2455124T5 (es) 2018-05-08
WO2011138419A1 (en) 2011-11-10
US9046538B2 (en) 2015-06-02
EP2567240B1 (en) 2018-04-04
US12025623B2 (en) 2024-07-02
CN102971633B (zh) 2016-08-10
US9459264B2 (en) 2016-10-04
EP2567240A1 (en) 2013-03-13
EP3399318A1 (en) 2018-11-07
ES2455124T3 (es) 2014-04-14
CA2798238A1 (en) 2011-11-10
EP2385374B2 (en) 2018-02-28
NO2567240T3 (zh) 2018-09-01
US20150247873A1 (en) 2015-09-03
US20160363601A1 (en) 2016-12-15
EP3399318B1 (en) 2020-03-04
DK2567240T4 (da) 2021-05-31
EP2385374A1 (en) 2011-11-09
CN102971633A (zh) 2013-03-13
US20210003598A1 (en) 2021-01-07

Similar Documents

Publication Publication Date Title
BR112013008959A2 (zh)
BR112012031500A2 (zh)
BR112012029986A2 (zh)
BR112012030039A2 (zh)
BR112012028408A2 (zh)
BR112012026492A2 (zh)
BR112012027808A2 (zh)
NO2567240T3 (zh)
BR112012025307A2 (zh)
BR112012019354A2 (zh)
BR112012026946A2 (zh)
BR112012017960A2 (zh)
BR112012025482A2 (zh)
BR112013006400A2 (zh)
BR112012031826A2 (zh)
BR112012028186A2 (zh)
BR112012025577A2 (zh)
BR112012018256A2 (zh)
BR112012027015A2 (zh)
BR112012025308A2 (zh)
BR112012027945A2 (zh)
BR112012024872A2 (zh)
BR112013010949A2 (zh)
BR112012023265A2 (zh)
BR112013003284A2 (zh)